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Abstract
OBJECTIVES: Using data obtained from a Japanese nationwide annual database with web-based data entry, we developed a risk model of
mortality and morbidity after lung cancer surgery.
METHODS: The characteristics and operative and postoperative data from 80 095 patients who underwent lung cancer surgery were
entered into the annual National Clinical Database of Japan data sets for 2014 and 2015. After excluding 1501 patients, the development
data set for risk models included 38 277 patients entering in 2014 and the validation data set included 40 317 patients entering in 2015.
Receiver–operating characteristic curves were generated for the outcomes of mortality and composite mortality/major morbidity. The
concordance index was used to assess the discriminatory ability and validity of the model.
RESULTS: The 30-day mortality and overall mortality rates, including in-hospital deaths, were 0.4% and 0.8%, respectively, in 2014, and 0.4%
and 0.8%, respectively, in 2015. The rate of major morbidity was 5.6% in 2014 and 5.6% in 2015. Several risk factors were significantly associated
with mortality, namely, male sex, performance status, comorbidities of interstitial pneumonia and liver cirrhosis, haemodialysis and the surgical
procedure pneumonectomy. The concordance index for mortality and composite mortality/major morbidity was 0.854 (P< 0.001) and 0.718
(P< 0.001), respectively, for the development data set and 0.849 (P< 0.001) and 0.723 (P< 0.001), respectively, for the validation data set.
CONCLUSIONS: This model was satisfactory for predicting surgical outcomes after pulmonary resection for lung cancer in Japan and will
aid preoperative assessment and improve clinical outcomes for lung cancer surgery.
Keywords: Risk model • Surgery • Lung cancer • Nationwide survey
INTRODUCTION
Lung cancer is a leading cause of death worldwide. Surgery remains
a mainstay for complete cure. Because of the large number of elderly
people in Japan, lung cancer patients frequently have multiple
comorbidities, which increase mortality and morbidity risks. Risk-
adjusted outcome analysis is demanding when used to assess pre-
operative risk, monitor surgical performance and implement meas-
ures that improve care.
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Table 1: Baseline characteristics
Risk model set (2014) Validation set (2015)
n % n %
Total 38 277 100 40 317 100
Age (years) ± SD 69.35 ± 9.31 69.6 ± 9.24
Male 23 639 61.8 24 819 61.6
BMI ± SD 22.7 ± 3.36 22.7 ± 3.37
Cigarette smoking 24 573 64.2 26 214 65.0
<10 pack-years 1841 4.8 2020 5.0
10–30 pack-years 4515 11.8 4877 12.1
30 pack-years or more 18 217 47.6 19 317 47.9
Cigarette smoking history
Past (stopped more than 30 days before) 20 171 52.7 22 050 54.7
Current 4402 11.5 4164 10.3
Never 13 704 35.8 14 103 35.0
PS
PS0 31 462 82.2 33 775 83.8
PS1 5285 13.8 5051 12.5
PS2 1240 3.2 1206 3.0
PS3 225 0.6 194 0.5
PS4 12 0.0 11 0.0
Not available 53 0.1 80 0.2
Comorbidities
Diabetes mellitus 5553 14.5 6111 15.2
Coronary artery disease 2037 5.3 2326 5.8
Haemodialysis 275 0.7 287 0.7
Liver cirrhosis (Child–Pugh Class B/C) 211 0.6 158 0.4
Interstitial pneumonia 1783 4.7 1836 4.6
Central nerve system disorder 2254 5.9 2461 6.1
Spirogram
%VC <80% 4261 11.1 4442 11.0
%FEV1 <70% 4787 12.5 5056 12.5
%FEV1 <70% 11 354 29.7 12 094 30.0
%FEV1 <50% 1090 2.8 1136 2.8
Induction treatment
Induction chemoradiotherapy 474 1.2 495 1.2
Induction chemotherapy 509 1.3 455 1.1
Induction radiotherapy 45 0.1 49 0.1
Clinical stage
IA 23 194 60.6 24 810.0 61.5
IB 7220 18.9 7640.0 18.9
IIA 2990 7.8 2984.0 7.4
IIB 1743 4.6 1742.0 4.3
IIIA 2447 6.4 2423.0 6.0
IIIB and IV 584 1.5 555.0 1.4
Approach
Mini-thoracotomy <8 cm 9806 25.6 9778 24.3
Complete VATS 15 078 39.4 16 848 41.8
Thoracotomy 13 393 35.0 13 691 34.0
Primary procedure
Wedge resection 5568 14.5 5930 14.7
Segmentectomy 4192 11.0 4253 10.5
Lobectomy 27 962 73.1 29 570 73.3
Sleeve lobectomy 491 1.3 548 1.4
Pneumonectomy 508 1.3 520 1.3
Nodal dissection
Not performed 6584 17.2 6951 17.2
Hilar dissection 5568 14.5 6012 14.9
Lobe-specific mediastinal dissection 15 539 40.6 17 410 43.2
Systematic mediastinal dissection 10 586 27.6 9944 24.7
Resectability
Complete resection 36 217 94.6 38 352 95.1
Incomplete resection 1557 4.1 1509 3.7
Unclassified 503 1.3 456 1.1
Hospital stratified by annual volume
Low: <50 operations (506 SUs in 2014 and 510 SUs in 2015) 9771 25.4 9768 24.2
Middle: 50–100 operations (195 SUs either in 2014 or in 2015) 13 584 35.5 13 785 34.2
High: >100 operations (96 SUs in 2014 and 109 SUs in 2015) 14 922 39.0 16 764 41.6
BMI: body mass index; VATS: video-assisted thoracic surgery; SUs: surgical units; SD: standard deviation; PS: performance status; FVC1: forced vital capacity in
1 s; VC: vital capacity. Clinical stage: 7th edition TNM classification by UICC.
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In 2011, the National Clinical Database (NCD) of Japan
adopted an annual web-based data collection system. The NCD
is a nationwide system that links data collection to the first level
of surgical specialization in the Japanese Surgical Board
Certification System. In 2014, data on 1.6 million surgical proced-
ures from more than 4000 hospitals were collected [1]. On the
basis of the existing NCD system, an NCD specializing in general
thoracic surgery was launched in 2014. The data registration sys-
tem and information recorded are described in detail in our pre-
vious report [2]. The NCD for general thoracic surgery is part of
the second level of specialization in general thoracic surgery and
the accreditation system for educational institutions. In total,
80 095 lung cancer operations were registered in the 2014 and
2015 data sets. More than 95% of all pulmonary resections for
lung cancer registered with the Regional Bureau of Health and
Welfare in Japan were accounted for in the NCD [3].
In this study, we used the NCD for general thoracic surgery to
develop and validate a model estimating individualized risk for
patients undergoing pulmonary resection for lung cancer.
MATERIALS AND METHODS
Patient population
The study population for the current analysis was derived from 2
annual data sets (2014 and 2015) that included information on
persons who underwent surgical resection for primary lung can-
cer (at 797 surgical units in 2014 and 814 surgical units in 2015).
Surgical approach was categorized as thoracotomy or as a min-
imally invasive approach, including complete video-assisted thor-
acoscopic surgery and mini-thoracotomy with a wound length of
8 cm or less. The variable ‘surgical approach’ was excluded in the
development of risk models, because decisions regarding surgical
approach were biased by variability in patient selection at the
different centres. The surgical procedures included wedge resec-
tion, segmentectomy, lobectomy, sleeve lobectomy, bilobectomy
and pneumonectomy. Sleeve lobectomy or bilobectomy was
entered as a simple variable (lobectomy or bilobectomy) in the
analysis, because decisions regarding selection of sleeve lobec-
tomy varied among centres and because few patients underwent
bilobectomy (n = 143 in 2014 and n = 134 in 2015). Nodal dissec-
tion was categorized as hilar, lobe-specific mediastinal or system-
atic, as shown in Table 1.
Patients were excluded if they had undergone procedures with
no curative intent (n = 363 in 2014 and n = 359 in 2015), extrap-
leural pneumonectomy, completion pneumonectomy, emer-
gency surgery or combined procedures for both lungs or if they
had been transported by ambulance. Of the 39 029 patients in
2014 and 41 016 patients in 2015 who were eligible for analysis,
1501 (n = 752 in 2014 and n = 749 in 2015) were excluded from
the analysis. The development data set for risk models included
38 277 patients entering in 2014, and the validation data set
included 40 317 patients entering in 2015.
Outcome measures
The primary outcome measures were operative mortality and the
composite outcome of mortality/major morbidity. Operative
mortality included patients who died within 30 days after sur-
gery, regardless of hospitalization status, and those who died
within the index hospitalization, even if death occurred after
transfer to another hospital.
Major morbidity was defined in accordance with the Society
of Thoracic Surgeons (STS) risk models as shown in Table 2 [4, 5].
Statistical analysis
For the multivariate logistic regression analysis, a risk model set,
registered in 2014 (n = 38 277), and a validation set, registered in
2015 (n = 40 317), were created to estimate associations of patient
Table 2: Frequency of major complications (rate)
Variable Values
Risk model set
(2014)
(n = 38 277)
Validation
set (2015)
(n = 40 317)
Total 2134 (5.6%) 2261 (5.6%)
Respiratory failure 220 (0.6%) 200 (0.5%)
Bronchopleural fistula 130 (0.3%) 129 (0.3%)
Pulmonary embolus 41 (0.1%) 32 (0.1%)
Pneumonia 713 (1.9%) 771 (1.9%)
Unexpected return to
operating room
83 (0.2%) 59 (0.1%)
Myocardial infarction 21 (0.1%) 17 (0.0%)
Atrial arrhythmia 627 (1.6%) 727 (1.8%)
Renal failure 33 (0.1%) 26 (0.1%)
Chylothorax 271 (0.7%) 271 (0.7%)
Postoperative blood
transfusion
148 (0.4%) 143 (0.4%)
Respiratory failure includes patients who required tracheal intubation,
tracheostomy or initial ventilatory support for longer than 48 h. Renal
failure includes patients who required haemodialysis postoperatively or
a postoperative increase in serum creatinine concentration to greater
than 4 mg/dl or 3 times the preoperative value.
Table 3: Mortality and major morbidity (rate)
Risk model set
(2014)
(n = 38 277)
Validation
set (2015)
(n = 40317)
Death within 30 days or
in hospital
315 (0.8%) 309 (0.8%)
In-hospital death 257 (0.7%) 264 (0.7%)
In-hospital death
within 30 days
96 (0.3%) 123 (0.3%)
In-hospital death
after 30 days
161 (0.4%) 141 (0.3%)
Death within 30 days 154 (0.4%) 168 (0.4%)
Major morbidity 2134 (5.6%) 2261 (5.6%)
Death within 30 days or
in hospital, or major
morbidity
2241 (5.9%) 2349 (5.9%)
In-hospital deaths include deaths during the index hospitalization even
if the patient died after transfer to another hospital.
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baseline characteristics with the primary outcome measures of
operative mortality and composite mortality/major morbidity.
The variables entered in the model were selected with the v2 test,
for categorical covariates, and the unpaired t-test, for continuous
covariates. All variables that were significant at P < 0.05 and were
present in at least 0.5% of the sample were included in the multi-
variate stepwise logistic regression analysis of both outcomes.
Missing or inconsistent values for age or spirography were substi-
tuted with the most frequent categories. Model discrimination
was assessed by examining the area under the receiver–operating
characteristics curve (C-statistic). Model variation was analysed
using the annual data registered in 2015. Analyses were per-
formed with the IBM SPSS Statistics software package (version
23; IBM Corp., Armonk, NY, USA).
RESULTS
Risk profile of study population
The number of patients who underwent lung cancer surgery was
38 277 in the risk model set (1 January 2014 through 31
December 2014) and 40 317 in the validation set (1 January 2015
through 31 December 2015). The baseline characteristics of these
patient groups were similar (Table 1).
Outcomes
The most frequent cause of major morbidity was respiratory fail-
ure after pneumonia and atrial arrhythmia (Table 2). In the risk
model set, there were 315 (0.8%) operative deaths, and major
morbidity was noted in 2134 patients (5.6%). In the validation
set, there were 309 (0.8%) operative deaths, and major morbidity
was noted in 2261 patients (5.6%) (Table 3). Mortality and major
morbidity rates were high in patients who underwent pneumon-
ectomy and not influenced by hospital volume (Table 4). More
than half of the dead patients died from respiratory-related
death, including acute exacerbation of interstitial pneumonia,
pneumonia and other respiratory failure. The outcomes of the 2
data sets were almost identical.
Model result
Multivariate risk models were developed, and the final logistic
model, with odd ratios and 95% confidence intervals (CIs), is pre-
sented in Table 5, which shows the associations of patient base-
line characteristics with the outcome measures of mortality and
mortality/major morbidity. Nineteen variables were associated
with mortality, and 25 variables were associated with mortality/
morbidity.
To evaluate model performance, we used the concordance
C-index (a measure of model discrimination), which is the area
under the receiver–operating characteristics curve. The C-indices
were 0.854 (95% CI, 0.835–0.874; P < 0.001) for mortality and
0.718 (95% CI, 0.708–0.729; P < 0.001) for mortality/major mor-
bidity. The C-indices in the validation data sets for these 2 mod-
els were 0.849 (95% CI, 0.830–0.868; P < 0.001) and 0.723 (95%
CI, 0.713–0.733; P < 0.001), respectively.
DISCUSSION
Surgery is a promising treatment for patients with early stage
lung cancer, even though some postoperative complications are
unavoidable. Risk ratios for postoperative complications are af-
fected by patient demographics, oncologic factors such as hist-
ology and staging, type of surgical procedure and surgeon
performance. The STS [5], the US National Cancer Database [6],
the European Society of Thoracic Surgeons (ESTS) [7] and institu-
tions in other countries [8] have developed risk models for lung
cancer surgery, to assess quality measures for surgeon perform-
ance and preoperative decision-making.
Obstacles to establishing optimal risk models
Several limitations in establishing ideal risk models have been
described [9], as follows:
(i) Risk models should be based on a large database covering as
many operations as possible. The criteria used to select patients
for surgery may vary by centre, which would have affected the
model. A clinical database will not yield an accurate risk model
Table 4: Mortality and major morbidity (rate), stratified by surgical procedure, resectability and hospital annual volume
Mortality Mortality and major morbidity
Risk model set (2014) Validation set (2015) Risk model set (2014) Validation set (2015)
Primary procedure
Wedge resection 27 (0.5%) 27 (0.5%) 138 (2.5%) 143 (2.4%)
Segmentectomy 17 (0.4%) 18 (0.8%) 168 (4.0%) 179 (4.2%)
Lobectomy 249 (0.9%) 243 (0.8%) 1837 (6.6%) 1931 (6.5%)
Pneumonectomy 20 (3.9%) 16 (3.1%) 90 (17.1%) 84 (16.2%)
Resectability
Complete resection 280 (0.8%) 280 (0.7%) 2017 (5.6%) 2149 (5.6%)
Incomplete resection 28 (1.8%) 22 (1.5%) 75 (4.8%) 85 (5.6%)
Unclassified 7 (1.4%) 7 (1.5%) 32 (6.4%) 27 (5.9%)
Hospital stratified by annual volume
Low: <50 operations 90 (0.9%) 86 (0.9%) 522 (5.3%) 525 (5.4%)
Middle: 50–100 operations 124 (0.9%) 106 (0.9%) 756 (5.6%) 739 (5.4%)
High: >100 operations 101 (0.7%) 117 (0.7%) 963 (6.5%) 1085 (6.5%)
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unless there is a high participation rate in data entry [2]. Different
investigators evaluating the same predictors by means of regres-
sion analysis might obtain heterogeneous results because of sam-
ple biases at the time of the traditional training-and-test method
for model building. To maintain statistical reliability and reproduci-
bility, bootstrap analysis is recommended [9]. In addition, the use of
different samples is recommended for model validation processes.
Data registered in the following year, 2015, were used for validation,
to show the reproducibility and reliability of our risk model.
(ii) The use of morbidity as an outcome is problematic.
Although it is defined in the manual for the case report form in
the NCD registration system [2], morbidity is subject to entry
error or under-reporting. In Japan, data managers receive in-
struction on the correct registration of postoperative complica-
tions, at the NCD seminar at the annual meeting of the Japanese
Association for Chest Surgery.
(iii) Important variables, such as a body mass index >35, are
not included in the present model because they are infrequent in
Table 5: Predictors of mortality and composite mortality/major morbidity
P-value OR (95% CI)
Mortality model
Male <0.001 2.366 (1.533–3.651)
Five-year increase in age (60–79 years) <0.001 1.420 (1.299–1.551)
PS
PS1 0.006 1.457 (1.113–1.908)
PS2 or higher <0.001 2.644 (1.836–3.806)
%VC 10% decrease (from 100% to 50%) <0.001 1.380 (1.277–1.491)
Liver cirrhosis (Child–Pugh Class B/C) 0.009 3.075 (1.320–7.161)
Haemodialysis 0.006 2.883 (1.357–6.125)
Interstitial pneumonia <0.001 3.690 (2.790–4.880)
Ischaemic heart disease (with/without intervention) 0.023 1.504 (1.057–2.140)
Smoking history 0.019 1.711 (1.093–2.677)
Tumour size >3 cm (radiological) 0.027 1.354 (1.036–1.771)
Clinical stage
II or higher 0.006 1.537 (1.130–2.091)
III or higher 0.009 1.568 (1.120–2.196)
Superior sulcus tumour 0.032 1.752 (1.048–2.931)
Surgical procedure
Right lower lobectomy 0.001 1.604 (1.213–2.122)
Lobectomy or bilobectomy <0.001 1.973 (1.382–2.816)
Pneumonectomy <0.001 5.224 (2.865–9.523)
Chest wall resection (other than first rib) <0.001 2.820 (1.584–5.019)
Histology other than adenocarcinoma 0.001 1.502 (1.181–1.911)
Mortality and morbidity model
Male <0.001 1.724 (1.519–1.917)
Five-year increase in age (60–79 years) <0.001 1.160 (1.124–1.197)
Cigarette smoking 30 pack-years or more <0.001 1.236 (1.105–1.382)
PS
PS1 0.001 1.228 (1.094–1.379)
PS2 or higher <0.001 1.473 (1.216–1.784)
%VC 10% decrease (from 100% to 50%) <0.001 1.148 (1.108–1.188)
%FEV1 <70% 0.002 1.164 (1.055–1.284)
%FEV1 <50% <0.001 1.506 (1.213–1.870)
Haemodialysis 0.003 1.847 (1.226–2.781)
Interstitial pneumonia <0.001 2.293 (1.978–2.658)
Stroke 0.040 1.182 (1.007–1.387)
Untreated diabetes mellitus 0.021 1.567 (1.069–2.299)
Autoimmune disease 0.016 1.405 (1.065–1.854)
Arrhythmia <0.001 1.849 (1.554–2.201)
Induction radiotherapy or chemoradiotherapy <0.001 1.762 (1.347–2.304)
Clinical Stage II or higher <0.001 1.341 (1.209–1.487)
Surgical procedure
Pneumonectomy <0.001 3.092 (2.296–4.165)
Lobectomy or bilobectomy <0.001 1.475 (1.248–1.743)
Nodal dissection
Hilar or lobe specific or systematic <0.001 1.999 (1.621–2.465)
Systematic <0.001 1.210 (1.096–1.335)
Combined resection
Pulmonary artery 0.019 1.721 (1.095–2.706)
Chest wall (other than first rib) 0.005 1.592 (1.152–2.199)
Chest wall (first rib) 0.004 2.584 (1.356–4.925)
Wedge resection or segmentectomy of lung <0.001 1.558 (1.222–1.986)
Histology other than adenocarcinoma <0.001 1.229 (1.115–1.354)
VC: vital capacity; FEV1: forced expiratory volume in 1 s; CI: confidence interval; PS: performance status; OR: odds ratio. Clinical stage: 7th edition TNM classification by UICC.
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the population [10]. The NCD does not include race or presence
of peripheral vascular disease among the preoperative vari-
ables. In addition, deep vein thrombosis and sepsis are not
included among postoperative complications. However, these
complications are rare in Japan. The STS and ESTS databases do
not include interstitial pneumonia or liver cirrhosis as variables
[5, 7], even though our model identified them as significant
risk factors for lung cancer surgery. These variations in risk
models, which are related to regional differences in data
collection, should be carefully reviewed. A worldwide clinical
database, with the same variables included in all countries, is
desirable [11].
(iv) Previously reported risk models by the STS and ESTS
defined operative mortality as death during the index hospital-
ization for surgery or within 30 days of the procedure. In our
database, operative mortality classified death after transfer to
another hospital over 30 days after surgery as an in-hospital
death. The universal health care system in Japan allows patients
with serious comorbidities or postoperative complications to
be transferred to another hospital. Mortality at 90 days after
thoracic surgery is twice that at 30 days [12]. In the present
study, the value for 30-day mortality plus in-hospital mortality
is double that for 30-day mortality and thus is likely to be ap-
proximate 90-day mortality.
(v) Data quality affects risk model analysis. Databases should
be audited regularly to maintain the quality of information; how-
ever, the audit of even a small fraction of a database requires
substantial effort. To reduce the burden of ensuring data quality,
a web audit system was developed for the Japan NCD system.
Surgeons provide anonymous operative notes of patients ran-
domly selected by the NCD, the number of which is equivalent
to approximately 0.5% of registered cases. These notes are sub-
mitted to the Japanese Board of General Thoracic Surgery at the
time of application for board certification for general thoracic
surgery. A committee authorized by the NCD determines inter-
rater reliability between these samples and Internet-based data
from the NCD. The results indicate that the correctness of data
on age, gender, procedure, disease, operative time, blood loss
and participating surgeons was greater than 94% [2]. Starting in
2017, the web audit will encompass other variables related to
patient demographics and outcomes, which will be evaluated
using hospitalization summaries randomly selected by the
NCD office.
The aim of this study was to use the comprehensive NCD on
general thoracic surgery to develop a risk model for lung cancer
patients undergoing pulmonary resection. The 30-day and the
rate of the composite outcome morbidity/major morbidity were
lower than those for the STS and ESTS databases, perhaps be-
cause of differences in clinical characteristics (such as body mass
index and comorbidities), clinical staging and type of surgery, i.e.
the so-called ‘cherry-picking’ problem. Patient demographics in
the NCD differed greatly from those in the STS and ESTS data-
base-based risk model of 2016, specifically the distributions of
patients undergoing induction treatment, thoracotomy and
pneumonectomy (Table 6) [5, 7]. Despite differences in operative
morbidity and mortality between the STS risk model and our
NCD model, there were several shared risk factors for operative
mortality and morbidity. If input items were standardized, a large
clinical database could overcome problems related to regional
disparities.
Older age and being male were predictors in both risk models
[5, 6]. Male sex has consistently been identified as a risk factor in
other models of lung cancer surgery risk. The fact that advancing
age had adverse effects on mortality and morbidity in the present
patients younger than 80 years but not in those aged 80 years or
older is likely attributable to selection bias. Physical performance
might be similar for surgical candidates in these age groups.
Interstitial pneumonia and comorbidities such as haemodialysis
and liver cirrhosis were significant risk factors. Interstitial pneu-
monia is diagnosed on the basis of a radiologic finding of a fi-
brotic shadow with traction bronchiolectasis in bilateral basal
segments, regardless of respiratory symptoms and diffusing cap-
acity of the lung carbon monoxide. Affected patients are suscep-
tible to lethal postoperative respiratory failure from acute
exacerbation of interstitial pneumonia [13]. The diffusing capacity
can be accepted as important predictors of operative mortality
and morbidity after lung cancer resection [7]; therefore, these
data have been documented since 2017.
Table 6: Comparison of risk models for pulmonary resection in selected large clinical databases
National Clinical Database Japan Society of Thoracic Surgeons (USA) European Society of Thoracic Surgeons
Data entry 78 594 27 844 47 960
No. of surgical units 799 231 >200
Survey (year) 2014–2015 2012–2014 2007–2015
Patients Primary lung cancer Primary lung cancer Anatomical lung resection
Age (years) ± SD 69.4 ± 9.3 67.2 ± 10.1 62.6 ± 11.4
Male 61.70% 45.40% 68.00%
BMI ± SD 22.7 ± 3.4 27.6 ± 6.2 25.5 ± 4.5
Coronary artery disease 5.50% 22.30% 7.70%
Renal failure 0.7% (haemodialysis) 1.80% 8.30%
Diabetes mellitus 14.80% 18.50% 2.80%
Induction treatment 2.50% 6.50% 9.90%
Thoracotomy 34.50% 38.40% 86.90%
Pneumonectomy 1.30% 4.00% 10.50%
Operative mortality 0.8% (30 days + in-hospital) 1.4% (30 days) 2.7% (30 days)
Major morbidity 5.60% 9.10% 18.40%
BMI: body mass index.
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Respiratory acidosis caused by respiratory failure is fatal for
patients undergoing maintenance haemodialysis who cannot
compensate for respiratory acidosis and hyperkalaemia by meta-
bolic alkalosis [14]. Child–Pugh Class B/C liver cirrhosis can cause
malnutrition, prolonged pleural discharge and bleeding and may
thus be a risk factor [15].
A tumour diameter >3 cm and a clinical stage of 2 or higher
are important variables relating to extensive resection and
are likely to be important risk factors. Evidence from numer-
ous studies indicates that minimally invasive surgery, including
video-assisted thoracoscopic surgery, has favourable effects on
mortality and morbidity. However, candidates for minimally in-
vasive surgery may be more likely to have early lung cancer.
Thus, the surgical approach should not be included in the risk
calculation because of likely selection bias and institutional bias.
Propensity-matched analysis is required in order to clarify risk
with respect to the use of a minimally invasive approach [16]. In
addition, because of the increasing number of patients with less
invasive adenocarcinoma, the variable non-adenocarcinoma was
identified as a risk factor.
Pneumonectomy resulting in cardiopulmonary dysfunction
and bronchopleural fistula is an important risk factor in lung can-
cer surgery [17]. In our model, other risk factors were right lower
lobectomy—which can result in the presence of a large pleural
dead space in the thoracic cavity, where bronchopleural fistulae
might develop [18]—and chest wall resections other than resec-
tion of the first rib, which may cause postoperative respiratory
failure [19].
Our analysis showed that risk models based on the NCD
2014 could be validated with the NCD 2015. Validation analysis
confirmed the feasibility of the risk model. However, patient
demographics, lung cancer oncology and treatment strategy,
among other factors, will continue to change as societies age
and medical science advances. Furthermore, the 8th edition of
the tumour, node and metastasis classification for lung cancer
was published by the International Association for the Study of
Lung Cancer. If adverse effects resulting in operative mortality
and morbidity are changing, the risk models for lung cancer
surgery will need to be reviewed, particularly in rapidly chang-
ing societies. Our NCD data collection system will continue to
enable data managers to respond to changes in data input, as
the system is able to annually update risk models for lung can-
cer surgery.
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APPENDIX. CONFERENCE DISCUSSION
Dr W. Weder (Zurich, Switzerland): Are you prospectively validating the quality of
your risk model, with other words, are you looking what’s happening to these
patients you have predicted a certain risk during a year?
Dr Endo: We performed just a retrospective analysis, not prospective.
Dr Weder: Yes, I understand, but are you now prospectively evaluating the
quality of the risk model?
Dr Endo: I hope so.
Dr Weder: And second question: did you look at the hospital-specific mortality,
especially at the risk of, was it dependent on the size? I have not seen it in the data.
Dr Endo: In our data, we cannot find the difference between hospitals
depending on volumes of surgery.
Dr K. Naunheim (St Louis, MO, USA): In the USA, we are also struggling
with quality improvement and feedback, and it is hard to know what to do
with this information. Our own databases, like yours, give the observed to
expected ratio and there is a statistical analysis that will tell you, just because
you are 1.1 or 1.2 does not mean you are outside the realm of good surgery.
Sometimes that could be just a statistical blip. I want to know whether you
have some method for statistically analysing the ODE. Do you feed that
information back to the surgeon, is that something they get and if they are
outside the bounds of acceptable practice, what sort of remediation, what
sort of help can you give them to try to bring them back to where they
should be, because it is not that they are bad people, they are necessarily
bad surgeons. Almost everybody who is a thoracic surgeon can be made
better. The whole idea of quality improvement is not punitive, is not to call
people names or kick them out of the profession, we need to re-educate
them and bring them back in, so I do not know whether you have any pro-
grammes to help re-educate surgeons.
Dr Endo: In our field of thoracic surgery, we do not perform such audit sys-
tems, to improve the surgical performance. But in the field of cardiovascular sur-
geries, the teams can advise the improvement of the hospital performance,
actually, in the last year. I also hope that if we find some bad hospital perform-
ance I can recommend some improvement.
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